Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VDJ001 in idiopathic multicentric Castleman disease (Phase III, randomized, double-blind, placebo-controlled)
CTR20254423Phase 3Active
- Sponsor
- Beijing VDJBio Co., Ltd.
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of VDJ-001 in idiopathic multicentric Castleman disease (iMCD), sponsored by Beijing VDJBio Co., Ltd.. Started Jan 2026; status: active.
02
Drugs
VDJ-001
03
Conditions
idiopathic multicentric Castleman disease (iMCD)
Beyond the preview
Go deeper on CTR20254423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254423.